The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 203-211

  Maduro, John H ^a   Noordhuis, Maartje G ^a   ten Hoor, Klaske A ^a   Pras, Elisabeth ^a   Arts, Henriette J G ^a   Eijsink, Jasper J H ^a   Hollema, Harry ^a   Mom, Constantijne H ^a   de Jong, Steven ^a   de Vries, Elisabeth G E ^a   de Bock, Geertruida H ^a   van der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cervical cancer; Death receptors; Immunohistochemistry; Radiotherapy; TRAIL

Indexed keywords

APOPTOSIS; CERVICAL CANCER; CERVICAL CANCERS; COMPLETE RESPONSE; DEATH RECEPTORS; DEATH-RECEPTOR; DISEASE-SPECIFIC SURVIVALS; DRUG TARGETS; IMMUNOHISTOCHEMISTRY; IMMUNOSTAINING; MULTI VARIATE ANALYSIS; ODDS RATIOS; SYNERGISTIC EFFECT; TISSUE MICROARRAYS; TRAIL; TUMOR CELLS; TUMOR NECROSIS FACTORS;

CELL DEATH; DECISION MAKING; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY;

TUMORS;

CARBOPLATIN; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CYTOPLASM; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; RADIOTHERAPY DOSAGE; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TISSUE ARRAY ANALYSIS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 68649113781     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.071     Document Type: Article

References (29)

1. Lehman M., and Thomas G. Is concurrent chemotherapy and radiotherapy the new standard of care for locally advanced cervical cancer?. Int J Gynecol Cancer 11 (2001) 87-99
2. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 358 (2001) 781-786
3. Maduro J.H., Pras E., Willemse P.H., et al. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29 (2003) 471-488
4. Hougardy B.M., Maduro J.H., van der Zee A.G., et al. Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: Changing the apoptotic balance. Lancet Oncol 6 (2005) 589-598
5. Duiker E.W., Mom C.H., de Jong S., et al. The clinical trail of TRAIL. Eur J Cancer 42 (2006) 2233-2240
6. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
7. Maduro J.H., de Vries E.G., Meersma G.J., et al. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int J Radiat Oncol Biol Phys 72 (2008) 543-552
8. Ashkenazi A., Holland P., and Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26 (2008) 3621-3630
9. Tolcher A.W., Mita M., Meropol N.J., et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25 (2007) 1390-1395
10. Reesink-Peters N., Hougardy B.M., van den Heuvel F.A., et al. Death receptors and ligands in cervical carcinogenesis: An immunohistochemical study. Gynecol Oncol 96 (2005) 705-713
11. Zhang X.D., Nguyen T., Thomas W.D., et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482 (2000) 193-199
12. Hougardy B.M., Reesink-Peters N., van den Heuvel F.A., et al. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer 123 (2008) 1457-1465
13. Koornstra J.J., Kleibeuker J.H., van Geelen C.M., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 200 (2003) 327-335
14. Ryu H.S., Chang K.H., Chang S.J., et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer 10 (2000) 417-424
15. Arts H.J., de Jong S., Hollema H., et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol 92 (2004) 794-800
16. Spierings D.C., de Vries E.G., Timens W., et al. Expression of TRAIL and TRAIL death receptors in Stage III non-small cell lung cancer tumors. Clin Cancer Res 9 (2003) 3397-3405
17. van Geelen C.M., Westra J.L., de Vries E.G., et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated Stage III colon cancer patients. J Clin Oncol 24 (2006) 4998-5004
18. McCarthy M.M., Sznol M., DiVito K.A., et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11 (2005) 5188-5194
19. Lancaster J.M., Sayer R., Blanchette C., et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 9 (2003) 762-766
20. Zhuang L., Lee C.S., Scolyer R.A., et al. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 37 (2006) 1286-1294
21. Trott K.R. Can tumour response be assessed from a biopsy?. Br J Cancer Suppl 4 (1980) 163-170
22. Saibishkumar E.P., Patel F.D., Sharma S.C., et al. Prognostic value of response to external radiation in Stage IIIB cancer cervix in predicting clinical outcomes: A retrospective analysis of 556 patients from India. Radiother Oncol 79 (2006) 142-146
23. Nijhuis E.R., van der Zee A.G., in 't Hout B.A., et al. Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys 66 (2006) 699-705
24. Moyses H.M., Morrow C.P., Muderspach L.I., et al. Residual disease in the uterus after preoperative radiotherapy and hysterectomy in Stage IB cervical carcinoma. Am J Clin Oncol 19 (1996) 433-438
25. Rouzier R., Morice P., De Crevoisier R., et al. Survival in cervix cancer patients treated with radiotherapy followed by radical surgery. Eur J Surg Oncol 31 (2005) 424-433
26. Oka K., Nakano T., and Hoshi T. Analysis of response to radiation therapy of patients with cervical adenocarcinoma compared with squamous cell carcinoma. MIB-1 and PC10 labeling indices. Cancer 77 (1996) 2280-2285
27. Straughn Jr. J.M., Oliver P.G., Zhou T., et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 101 (2006) 46-54
28. Greco F.A., Bonomi P., Crawford J., et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61 (2008) 82-90
29. Plummer R., Attard G., Pacey S., et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13 (2007) 6187-6194